IMU Biosciences has secured £11.5 million in its Series A financing round.
The acquisition marks a pivotal expansion for the company into the US market.
CellVoyant has raised £7.6 million in seed funding to speed up the development of novel cell therapies.
The largest biotech hub is set to be built in Lithuania by Northway Group.
Hovione has acquired start-up company, ExtremoChem, expanding its technology platforms.
UK industry body, ABPI, has responded positively to the recent Autumn Statement.
Innovative strategies and good partnerships are means by which developers can overcome the unique challenges in biologics formulation.
The companies will co-promote GSK’s shingles vaccine, Shingrix, to healthcare professionals and points of vaccination in China.
Orakl Oncology has raised funds to develop its precision oncology platform and accelerate drug development.